 Millions of people have gum disease, and age is a leading risk factor. The condition is linked to higher risk of heart disease and perhaps dementia, too. Dr. Jonathan Ahn at the University of Washington and his collaborators have FDA approval to study rapamycin in adults 50 and older with gum disease, which may offer clues for treating or slowing down other age-related conditions.